Skip to main content
Fig. 1 | The Journal of Headache and Pain

Fig. 1

From: Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis

Fig. 1

Model structure. All patients start preventive migraine treatment. Patients who at the end of 12 weeks have been classified as responders were assessed in the long term whether they remained on treatment or discontinued. Non-responders went directly to discontinuation status. Mortality was not considered as an individual health state, since this can occur to all patients, whatever their health status may be. Thus, the absorbing state for mortality is negative discontinuation

Back to article page